NCT06471868进行中（未招募）1 期
An Open-label, Randomized, Multiple-dose, 2-sequence, 2-period, Crossover, Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetics of IY-HCR21 Compared to IY-MIC in Healthy Adult Volunteers
Il-Yang Pharm. Co., Ltd.1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2024年6月10日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Betanechol AUCt,ss
研究概览
简要总结
This study evaluate the pharmacokinetic and safety of IY-HCR21
详细描述
Phase 1 study to evaluate the safety and the pharmacokinetics of IY-HCR21 in healthy adult volunteers under multiple-dose condition
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Volunteers aged 19 years and above at screening
- •A volunteer who weighs ≥ 50kg (≥ 45kg for women) and has a body mass index(BMI)* of ≥18.0 and ≤ 30 at screening
- •*BMI(body mass index, kg/m^2)= Body weight (kg)/[height (m)^2]
- •No clinically significant congenital or treatment-requiring chronic medical conditions and no pathological symptoms or findings on internal medicine examination (including EEG, electrocardiogram, thoracic and gastroscopy or gastrointestinal radiology, if necessary)
- •A person who is determined by the principal investigator (or a physician delegated by the principal investigator) to be suitable as a patient as a result of diagnostic tests (e.g., haematology, blood chemistry, serology, urinalysis) and electrocardiograms (ECG) set and conducted according to the characteristics of the investigational drug at the time of screening.
- •Agree that they or their spouse or partner is using a medically accepted method of contraception* (but not hormonal agents) to exclude the possibility of pregnancy from the date of the first dose of investigational drug until 7 days after the last dose of investigational drug, and agree not to provide sperm or eggs
- •Signed the consent form freely and voluntarily after being fully informed and understanding the purpose, content, characteristics of the investigational drug, and expected adverse events of this study.
排除标准
- •Have taken drugs that induce or inhibit drug metabolising enzymes, such as barbiturates, within 30 days prior to study entry (first dose day) or have taken drugs that may interfere with this study within 10 days prior to study entry (first dose day)
- •Participated in a bioequivalence study or other clinical trial within 6 months prior to study initiation (first dose) and received an investigational product
- •blood donation within 8 weeks prior to study entry (first dose day) or component donation within 2 weeks
- •Have a history of gastrointestinal surgery (except appendectomy and hernia surgery) that may affect the absorption of the drug
- •Excessive alcohol consumption within 1 month prior to study entry (first dose day)
- •Patients with any of the following conditions
- •Patients with mechanical obstruction of the gastrointestinal tract or urinary tract
- •spastic gastrointestinal diseases, stomach ulcers, acute inflammatory diseases of the gastrointestinal tract
- •Patients with peritonitis
- •Patients with vasovagal dystonia
- •Patients with asthma
- •Patients with hyperthyroidism
- •Patients with coronary artery occlusion
- •Bradycardia, atrioventricular conduction disorder, vasomotor instability
- •Hypotension, hypertension
- •Patients with myocardial infarction, severe heart disease
- •Patients with epilepsy and parkinsonism
- •Patients treated with anticholinesterase agents
- •Patients with unhealed gastrointestinal anastomoses
- •Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
- •Patients who are hypersensitive to or have a history of allergy to Yellow No. 4 (tartrazine)
- •Patients with a history of hypersensitivity to any of the main ingredients or excipients of this medicine
- •Have a history of clinically significant psychiatric disorders
- •For reasons other than the above inclusion/exclusion criteria, the principal investigator (or delegated investigator) deems the subject unsuitable for this study.
- •For female volunteers, suspected pregnancy or lactation
研究组 & 干预措施
A group
Active Comparator
Period 1 : IY-HCR21 1Tab, BID
Period 2 : IY-MIC 1Tab, QID
干预措施: IY-HCR21 (Drug)
A group
Active Comparator
Period 1 : IY-HCR21 1Tab, BID
Period 2 : IY-MIC 1Tab, QID
干预措施: IY-MIC (Drug)
B group
Active Comparator
Period 1 : IY-MIC 1Tab, QID
Period 2 : IY-HCR21 1Tab, BID
干预措施: IY-HCR21 (Drug)
B group
Active Comparator
Period 1 : IY-MIC 1Tab, QID
Period 2 : IY-HCR21 1Tab, BID
干预措施: IY-MIC (Drug)
结局指标
主要结局
Betanechol AUCt,ss
时间窗: Day 1 : Predose(0 hour), Day 2 : Predose(0 hour) Day 3 : Predose(0 hour), Afterdose (0.5, 1, 1.5, 2, 2.5, 3, 4, 4.5, 5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 16.5, 17, 18, 18.5, 19, 19.5, 20, 20.5, 21, 22, 24, 36, 48)
Betanechol AUCt,ss(Area under the plasma drug concentration-time curve in steady state)
Betanechol Cmax,ss
时间窗: Day 1 : Predose(0 hour), Day 2 : Predose(0 hour) Day 3 : Predose(0 hour), Afterdose (0.5, 1, 1.5, 2, 2.5, 3, 4, 4.5, 5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 16.5, 17, 18, 18.5, 19, 19.5, 20, 20.5, 21, 22, 24, 36, 48)
Betanechol Cmax,ss (Maximum plasma concentration in steady state)
次要结局
- AUCinf(Day 1 : Predose(0 hour), Day 2 : Predose(0 hour) Day 3 : Predose(0 hour), Afterdose (0.5, 1, 1.5, 2, 2.5, 3, 4, 4.5, 5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 16.5, 17, 18, 18.5, 19, 19.5, 20, 20.5, 21, 22, 24, 36, 48))
- Tmax,ss(Day 1 : Predose(0 hour), Day 2 : Predose(0 hour) Day 3 : Predose(0 hour), Afterdose (0.5, 1, 1.5, 2, 2.5, 3, 4, 4.5, 5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 16.5, 17, 18, 18.5, 19, 19.5, 20, 20.5, 21, 22, 24, 36, 48))
- t1/2(Day 1 : Predose(0 hour), Day 2 : Predose(0 hour) Day 3 : Predose(0 hour), Afterdose (0.5, 1, 1.5, 2, 2.5, 3, 4, 4.5, 5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 16.5, 17, 18, 18.5, 19, 19.5, 20, 20.5, 21, 22, 24, 36, 48))
- AUCt/AUCinf(Day 1 : Predose(0 hour), Day 2 : Predose(0 hour) Day 3 : Predose(0 hour), Afterdose (0.5, 1, 1.5, 2, 2.5, 3, 4, 4.5, 5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 16.5, 17, 18, 18.5, 19, 19.5, 20, 20.5, 21, 22, 24, 36, 48))
- AUC24(Day 1 : Predose(0 hour), Day 2 : Predose(0 hour) Day 3 : Predose(0 hour), Afterdose (0.5, 1, 1.5, 2, 2.5, 3, 4, 4.5, 5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 16.5, 17, 18, 18.5, 19, 19.5, 20, 20.5, 21, 22, 24))
- Cmin,ss(Day 1 : Predose(0 hour), Day 2 : Predose(0 hour) Day 3 : Predose(0 hour), Afterdose (0.5, 1, 1.5, 2, 2.5, 3, 4, 4.5, 5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 16.5, 17, 18, 18.5, 19, 19.5, 20, 20.5, 21, 22, 24, 36, 48))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
YH4808 Postprandial PK/PD Study in Healthy SubjectsHealthyNCT01761513Yuhan Corporation21
已完成
1 期
Study to Evaluate the Safety and Pharmacodynamic/Pharmacokinetic Characteristics of HIP2101 in Healthy VolunteersHealthy Adult VolunteerNCT04967014Hanmi Pharmaceutical Company Limited32
已完成
1 期
Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve SubjectsHepatitis CNCT01445795Bristol-Myers Squibb50
Unknown
1 期
A Study to Investigate the Safety, Tolerability, Pharmacokinetics of Single and Multiple Doses of Hepenofovir Fumarate Tablets in Healthy Volunteers.Chronic Hepatitis bNCT04277897Xi'an Xintong Pharmaceutical Research Co.,Ltd.69
已完成
1 期
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HR011408 at Two Formulations in Healthy SubjectDiabetes in AdultsNCT05147259Jiangsu HengRui Medicine Co., Ltd.62